Alzeca Biosciences develops novel advanced imaging agents for the early diagnosis of neurodegenerative diseases, including Alzheimer’s Disease. Alzheimer’s affects approximately 5.5M Americans at a cost of over $226 billion in care, and affects over 27 million patients worldwide. Its incidence is projected to quadruple by 2050 with costs exceeding$1 trillion in the US alone, unless a more effective diagnostic and treatment method is achieved.

Biotechnology

Health Care

Health Diagnostics

Alzeca Biosciences

Carlo Medici

Jason Eriksen

The Scientific Advisory Team at Alzeca Biosciences provides expert guidance on research and development strategies for advanced imaging agents used in the early diagnosis of neurodegenerative diseases, including Alzheimer's Disease. The team evaluates scientific data, advises on clinical trial designs, and collaborates on innovative approaches to enhance diagnostic accuracy and efficacy, ultimately aiming to improve patient outcomes and reduce healthcare costs.

Scientific Advisory Team

About

Team members